Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance
Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance
Tuesday, AngioDynamics Inc (NASDAQ: ANGO) reported a fourth-quarter 2024 adjusted EPS loss of $0.05, compared to the consensus loss of $0.16.
週二，AngioDynamics公司（納斯達克：ANGO）報告稱，2024年第四季度的調整後每股收益虧損5美分，與共識虧損16美分相比。
Fourth-quarter sales totaled $70.98 million, beating the analyst consensus of $70.89 million, according to data from Benzinga Pro.
第四季度銷售額爲7098萬美元，超過分析師共識的7089萬美元，根據Benzinga Pro的數據。
Pro forma net sales rose 1.9% to $71.1 million. Med Tech segment net sales were $29.3 million, up 11.3% year over year.
按比例計算的淨銷售額增長1.9%，達到7110萬美元。醫療技術業務部門的淨銷售額爲2930萬美元，同比增長11.3%。
Growth was driven by Auryon sales of $13.0 million, which increased 12.0%, NanoKnife disposable sales of $5.4 million, representing an increase of 18.0% compared to the fourth quarter of fiscal 2023, and AlphaVac sales of $1.9 million, an increase of 6.8% over the prior year.
創業板來自Auryon 1300萬美元的銷售增長12.0％，NanoKnife一次性銷售額爲540萬美元，比2023財年第四季度增長18.0％，AlphaVac銷售額爲190萬美元，比去年同期增長6.8％，這些是增長的驅動因素。
Med Device net sales were $41.8 million, a decrease of 3.8% compared to $43.4 million in the prior-year period.
Med Device淨銷售額爲4180萬美元，比上年同期下降3.8％，相比去年4340萬美元。
AngioDynamics also announced a stock repurchase program of up to $15.0 million.
AngioDynamics還宣佈推出最高1500萬美元的股票回購計劃。
Also Read: AngioDynamics Resolves Decade-Long Patent Litigation With Becton, Dickinson In Settlement Agreement.
還閱讀：AngioDynamics與Becton，Dickinson達成和解協議，解決了長達十年的專利訴訟。
"We view 2025 as an inflection point in the trajectory of our business...The increased scale of our Med Tech business, in combination with the optimization of our Med Device business, will allow us to begin to see increasing leverage as we exit the year. Operationally, we will continue to work through the transition of our manufacturing model to reduce overhead costs and improve margins in 2026 and beyond," commented Jim Clemmer, President and CEO.
“我們認爲2025年是我們業務軌跡的一個轉折點......我們醫療技術業務的規模增加，加上我們醫療器械業務的優化，將使我們能夠開始在完成這一年之際看到越來越多的槓桿效應。在運營方面，我們將繼續通過轉型我們的製造模式來減少運營成本並在2026年及以後改善利潤率，”Jim Clemmer總裁兼首席執行官發表了上述評論。
Guidance: AngioDynamics expects its fiscal year 2025 net sales of $282 million-$288 million, up 4.2%–6.4% year over year from 2024 pro forma revenue of $270.7 million and compared to the consensus of $287.68 million.
指引：AngioDynamics預計其2025財年淨銷售額爲28200萬-28800萬美元，比2024年按比例計算的收入27070萬美元同比增長4.2%-6.4%，而共識則爲28768萬美元。
The outlook includes Med Tech net sales to increase 10%-12%, and Med Device net sales are expected to grow 1%-3%.
展望包括醫療技術淨銷售增長10%-12%，醫療器械淨銷售預計增長1%-3%。
Gross margin is expected to be approximately 52% to 53% for fiscal year 2025. Adjusted EBITDA loss of $2.5 million to $0, compared to a pro forma adjusted EBITDA loss of $3.2 million a year ago.
預計2025財年的毛利率約爲52％至53％。與去年同期的按比例計算的320萬美元調整後EBITDA虧損相比，預計EBITDA虧損爲250萬美元至0。
AngioDynamics forecasts fiscal year 2025 adjusted EPS loss of $0.38-$0.42, compared to fiscal 2024 pro forma adjusted EPS loss of $0.45 and consensus loss of $0.49.
AngioDynamics預測2025財年調整後每股收益虧損0.38-0.42美元，而2024財年按比例計算的調整後每股收益虧損爲0.45美元，共識虧損爲0.49美元。
Price Action: ANGO shares are up 25.6% at $7.445 at last check Tuesday.
股票表現：ANG0股票週二最後交易價爲7.445美元，上漲了25.6%。
- Morgan Stanley Q2 Earnings: Higher Profits As Investment Banking Activity Rebounds, On Track To Reach $10T Client Assets.
- 大摩資源lof的Q2收益：隨着投資銀行業務的復甦，利潤增長，有望達到10萬億客戶資產。